EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Host cell entry receptors as pharmacological targets in respiratory viral infections: from biology to clinical translation

Sherif A El-Kafrawy, Norah A Othman, Mustafa Zeyadi, Mai M El-Daly, Esam I Azhar

Frontiers in Cellular and Infection Microbiology · 18.08.2026 · 16

DOI: 10.3389/fcimb.2026.1904701 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 18.08.2026. Verfasst von Sherif A El-Kafrawy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Special Infectious Agents Unit-BSL3, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Antiviral Agents, Virus Internalization, Receptors, Virus, Respiratory Tract Infections. Die Arbeit nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Abdulaziz University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory viral infections caused by seasonal influenza, respiratory syncytial virus (RSV), and pandemic-potential coronaviruses are responsible for several million hospitalisations and an estimated several hundred thousand deaths each year, a burden underscored by the severe 2024–2025 influenza season and the continued emergence of zoonotic threats such as clade 2.3.4.4b H5N1. This review critically examines the pharmacological basis for targeting host cell-surface receptors as a strategy for the treatment and prophylaxis of respiratory viral infections, evaluates the current evidence for each major receptor axis, and identifies the key translational gaps that must be addressed. Respiratory viruses, including influenza, RSV, SARS-CoV-2, and MERS-CoV, collectively cause millions of hospitalisations annually, and the persistent challenges of antigenic drift, zoonotic emergence, and antiviral resistance highlight the need for mechanistically distinct strategies. Host-directed therapies (HDTs) targeting conserved receptors (ACE2, DPP4, sialic acids, TMPRSS2) exploit genetically stable host factors required for viral entry. Across the receptor axes reviewed here, we appraise more than a dozen candidate agents spanning preclinical development through Phase III evaluation, including TMPRSS2 inhibitors, soluble ACE2 decoys, anti-CD147 and receptor-blocking monoclonal antibodies, the sialidase fusion protein DAS181, and avian IgY preparations. This evidence reveals a consistent gap between robust preclinical activity and as-yet-limited clinical efficacy. We conclude that host receptor targeting is a mechanistically rational but still clinically unproven component of the respiratory antiviral landscape; its value is most plausibly realised in defined niches—prophylaxis, early outpatient treatment, and combination with direct-acting antivirals—and within pandemic preparedness frameworks, provided that the safety, delivery, and trial-design challenges identified here are resolved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsVirus InternalizationReceptors, VirusRespiratory Tract InfectionsHumansAnimalsDipeptidyl Peptidase 4Host-Directed TherapyAngiotensin-Converting Enzyme 2Serine EndopeptidasesSARS-CoV-2Respiratory Syncytial Virus InfectionsMiddle East Respiratory Syndrome CoronavirusHost-Pathogen InteractionsInfluenza, HumanCoronavirus Infections

Stichwörter der Autor:innen

ACE2DPP4IgY antibodiesMERS-CoVRSVclinical translationhost-directed therapypandemic preparedness

Substanzen

Antiviral AgentsReceptors, VirusDipeptidyl Peptidase 4Angiotensin-Converting Enzyme 2Serine EndopeptidasesTMPRSS2 protein, humanDPP4 protein, human

Autor:innen und Institutionen

  • Special Infectious Agents Unit-BSL3, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.

Förderung

  • King Abdulaziz University

Zitieren

APA

El-Kafrawy, S. A., Othman, N. A., Zeyadi, M., El-Daly, M. M., & Azhar, E. I. (2026). Host cell entry receptors as pharmacological targets in respiratory viral infections: from biology to clinical translation. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1904701

Vancouver

El-Kafrawy SA, Othman NA, Zeyadi M, El-Daly MM, Azhar EI. Host cell entry receptors as pharmacological targets in respiratory viral infections: from biology to clinical translation. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1904701

BibTeX
@article{ElKafrawy2026,
  author = {El-Kafrawy, Sherif A and Othman, Norah A and Zeyadi, Mustafa and El-Daly, Mai M and Azhar, Esam I},
  title = {Host cell entry receptors as pharmacological targets in respiratory viral infections: from biology to clinical translation},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.1904701}
}
Kostenlos starten →